Clinical Guides
Paget Disease of Bone
A clinically focused guide to recognising, staging and managing adult Paget disease of bone in India, with explicit treatment controversies, bisphosphonate safeguards and escalation for fracture, neurological compromise or malignant transformation.
MedNext Academy | 13 min read
Paget Disease of Bone
A clinically focused guide to recognising, staging and managing adult Paget disease of bone in India, with explicit treatment controversies, bisphosphonate safeguards and escalation for fracture, neurological compromise or malignant transformation.
Summary
Paget disease of bone is a focal disorder of accelerated and disorganised bone remodelling. Excess osteoclastic resorption is followed by exuberant formation of woven and lamellar bone in a structurally abnormal mosaic. One bone or several bones may be involved, commonly the pelvis, spine, skull, femur or tibia. Many people are asymptomatic and are discovered through raised alkaline phosphatase or characteristic imaging; others develop focal bone pain, deformity, secondary osteoarthritis, hearing impairment, fracture or neurological compression.
Diagnosis is usually established by a characteristic plain radiograph. Total serum alkaline phosphatase, interpreted with liver tests, is the first-line activity marker; a bone-specific formation marker can help when liver disease confounds the result or limited monostotic disease leaves total alkaline phosphatase normal. Radionuclide bone scanning maps skeletal extent after diagnosis but is not sufficiently specific to replace targeted radiographs. CT or MRI answers a complication or differential question rather than serving as routine screening.
Treatment decisions are clinical, not biochemical reflexes. The 2019 international guideline recommends bisphosphonates for Paget-related bone pain and favours zoledronic acid for pain response, while finding insufficient evidence for intensive treat-to-target biochemical suppression in asymptomatic disease. A 2024 Italian position paper is more willing to treat active disease broadly. This disagreement must be discussed, not hidden. This reviewed draft has been reviewed by the MedNext Clinical Team and cannot prescribe an infusion or determine an individual Indian pathway.
How Common Is It?
Paget disease is strongly age-related and is rarely clinically apparent before 40 years. Historically it has been most frequent in Britain, parts of Western Europe, populations of European ancestry in North America, Australia and New Zealand, with a modest male predominance. Prevalence and clinical severity have declined in several high-incidence regions over recent decades for reasons that remain uncertain. Geographical clustering and familial aggregation support genetic susceptibility interacting with unidentified environmental factors.
The condition appears uncommon in India, but the evidence base is fragmented. Hospital case series and isolated reports cannot measure national prevalence across a large, genetically and geographically diverse population. Limited recognition, selective alkaline phosphatase testing and radiographic misclassification can contribute to underdiagnosis, while applying European prevalence estimates would exaggerate certainty. A raised alkaline phosphatase in an older Indian adult is much more often explained by hepatic or other bone conditions than by Paget disease; the diagnosis still deserves consideration when imaging is typical.
Reported prevalence also depends on whether surveys use radiographs, death records, biochemical screening or clinically diagnosed cases. Asymptomatic lesions create ascertainment bias, and monostotic disease may not raise total alkaline phosphatase. Service data should therefore describe the case definition, age, affected sites, symptoms, imaging and biochemical activity rather than quote a bare percentage. The useful epidemiological lesson is calibrated suspicion: Paget disease is rare in many Indian settings but not impossible, and characteristic focal bone enlargement, bowing, skull change or an unexplained bone-derived alkaline phosphatase elevation warrants structured evaluation.
Risk Factors
Advancing age is the strongest clinical association. Family history is important: pathogenic or susceptibility variants, especially involving SQSTM1, occur in a subset of familial disease and are associated with osteoclast signalling. Inheritance shows incomplete penetrance, so a variant does not predict that every relative will develop clinical disease. The 2019 guideline did not recommend routine genetic testing in ordinary clinical care because evidence that screening improves outcomes was insufficient. Selected families with early, severe or extensive disease may be referred to genetics or a specialist research pathway.
Sex and ancestry influence background probability, but neither confirms nor excludes the diagnosis. Environmental hypotheses, including viral triggers, have been investigated without establishing a single preventable cause. Paget disease is not caused by routine mechanical use of a bone, dietary calcium deficiency or ageing alone. A remote fracture can distort anatomy, but it does not create the characteristic remodelling disorder.
Risk of complications depends more on site and activity than on the diagnostic label alone. Weight-bearing long-bone involvement can cause bowing, fissure fracture and secondary joint disease. Skull disease can affect hearing; spinal disease may narrow foramina or the canal. High turnover, active lytic change and extensive lesions increase clinical concern, while an inactive incidental lesion may never become symptomatic. Before bisphosphonate therapy, renal impairment, hypocalcaemia, vitamin D deficiency, dental status and previous antiresorptive exposure influence safety. A sudden change in long-standing pain, swelling or radiographic pattern is not merely a risk factor; it is a red flag for fracture or rare sarcomatous transformation.
Diagnosis
History
Clarify why Paget disease is suspected: focal pain, deformity, hearing change, fracture, incidental radiograph or isolated alkaline phosphatase elevation. Map pain precisely and distinguish deep bone pain from adjacent joint pain, radicular symptoms and muscular pain. Ask about skull enlargement, hat-size change, tinnitus, dental problems, limb bowing, gait, falls and neurological symptoms. Record duration, previous images, family history and medicines. Constitutional symptoms or rapid escalation require an alternative or complicating diagnosis.
Examination
Inspect and palpate symptomatic bones for enlargement, bowing, warmth and focal tenderness. Assess adjacent joints, limb length, gait and fracture risk. With skull disease, examine cranial nerves and arrange formal hearing evaluation when indicated; bedside tests do not replace audiology. Spinal involvement requires a complete neurological examination. A new mass, marked swelling or severe focal tenderness needs urgent imaging. Examine for other causes of raised alkaline phosphatase, including hepatobiliary disease, rather than assuming skeletal origin.
Investigations
Obtain plain radiographs of suspicious regions. Typical evolution includes osteolysis, mixed lytic-sclerotic change, cortical thickening, trabecular coarsening, expansion and deformity. After radiographic diagnosis, a radionuclide bone scan identifies the extent of metabolically active involvement; radiograph scan-positive sites when the appearance is uncertain. Measure total alkaline phosphatase with liver tests. If normal despite high suspicion or confounded by liver disease, consider bone-specific alkaline phosphatase, PINP or resorption markers. Check calcium, phosphate, creatinine and vitamin D before therapy. CT or MRI evaluates fracture, stenosis, neural compression or suspected neoplasm. Biopsy is reserved for atypical or aggressive lesions.
Differential Diagnosis
Bone metastases can produce sclerosis, lysis, pain and raised alkaline phosphatase, but distribution and radiographic morphology differ. Prostate metastases, breast cancer, myeloma and primary bone tumours require clinical correlation and oncological work-up. Fibrous dysplasia may expand bone and produce ground-glass change, often presenting earlier. Hyperostosis frontalis interna, osteopetrosis and other sclerosing dysplasias have different patterns. Chronic osteomyelitis can cause sclerosis, expansion and pain, particularly when infection risk or a sinus is present.
Osteomalacia causes defective mineralisation with diffuse pain, weakness, Looser zones and calcium-phosphate-vitamin D abnormalities rather than the focal coarsened architecture of Paget disease. Primary hyperparathyroidism may increase bone turnover; renal osteodystrophy adds kidney and mineral abnormalities. Healing fractures and recent orthopaedic surgery can raise alkaline phosphatase. Hepatic cholestasis is a common biochemical mimic and is separated through liver enzymes, gamma-glutamyl transferase or a bone-specific marker. Normal calcium is usual in uncomplicated Paget disease; hypercalcaemia should prompt immobility, hyperparathyroidism, malignancy or another cause.
Degenerative osteoarthritis frequently coexists next to affected bone and may be the actual pain generator. Spinal stenosis, radiculopathy, vascular claudication and neuropathy require independent evaluation. Radiographic enlargement of the skull can resemble meningioma-associated hyperostosis or metastasis. Rare Paget-associated osteosarcoma presents with new severe pain, swelling, cortical destruction or soft-tissue mass. Giant-cell tumour is another uncommon complication. When imaging is atypical, rapidly changing or discordant with the biochemical picture, seek musculoskeletal radiology and orthopaedic oncology review rather than treating a presumed metabolic flare.
Management
Begin by deciding what requires treatment: Paget-related bone pain, an active lesion in a clinically consequential site, a complication, adjacent joint disease or no current symptom. Education should explain the focal nature, expected monitoring and symptoms that merit reassessment. Use appropriate analgesia, physiotherapy, gait support and falls prevention. Treat osteoarthritis, hearing impairment and fracture through their own pathways; suppression of bone turnover does not reliably reverse established deformity, deafness or degenerative cartilage disease.
The strongest current evidence supports a nitrogen-containing bisphosphonate for bone pain attributed to active Paget disease. The 2019 international guideline identifies a single intravenous zoledronic acid course as most likely to produce a favourable and durable pain response when not contraindicated. It recommends symptom improvement over normalisation of alkaline phosphatase as the treatment goal and rejects intensive biochemical treat-to-target therapy for preventing complications because clinical benefit was not shown. Repeat therapy should be based on recurrent Paget-related symptoms and objective activity, not an isolated marker drift.
A 2024 SIOMMMS position paper recommends broader treatment of newly diagnosed active disease, including selected asymptomatic patients, reflecting different interpretation of limited evidence and the durability of potent therapy. An Indian clinician should make this uncertainty explicit and individualise by site, lytic activity, age, comorbidity, access and patient preference. Orthopaedic surgery may be required for fracture, severe deformity or secondary joint destruction. Preoperative antiresorptive use is not automatic: evidence for reducing surgical blood loss is conflicting, and the metabolic bone and surgical teams should agree the plan.
Prescribing Information
Zoledronic acid for Paget disease is an intravenous prescription requiring confirmation of diagnosis, indication and current product label. Before administration, check creatinine and renal suitability, corrected calcium, phosphate, vitamin D status, hydration, pregnancy potential where relevant and active dental or systemic illness. Correct hypocalcaemia and clinically important vitamin D deficiency first. Ensure adequate calcium and vitamin D intake around treatment according to the specialist protocol. Avoid duplicate antiresorptive courses by reconciling hospital, osteoporosis and private prescriptions.
A transient acute-phase reaction with fever, myalgia and flu-like symptoms is common after the first zoledronic acid infusion; patients need anticipatory advice and a route for help. Serious risks include hypocalcaemia, kidney injury, uveitis, osteonecrosis of the jaw and atypical femoral fracture, although the latter two are uncommon in the limited exposure typically used for Paget disease. Severe eye pain or visual change after infusion requires urgent examination. Dental assessment is risk-based and should not create indefinite delay when treatment is clinically important.
Oral risedronate or other bisphosphonates may be alternatives where licensed and appropriate, but formulation, administration, renal and upper-gastrointestinal constraints differ. Calcitonin has a limited modern role when bisphosphonates are unsuitable and requires specialist justification. Do not prescribe solely to chase alkaline phosphatase into the reference range. After treatment, follow pain and an agreed biochemical marker; marker suppression is not proof that every symptom was Paget-related. Exact dosing, infusion duration, retreatment interval and renal thresholds must come from the current Indian-approved product information and the treating service.
When to Refer
Refer a patient with characteristic imaging, suspected Paget disease or an unexplained bone-derived alkaline phosphatase elevation to endocrinology, rheumatology, metabolic bone medicine or an experienced physician. The referral should include symptoms, affected sites, total alkaline phosphatase trend, liver profile, calcium, phosphate, creatinine, vitamin D, medicines and actual radiographs. Ask a defined question: confirm diagnosis, map extent, determine whether pain is metabolically active disease, assess infusion safety or investigate an atypical lesion.
Audiology and ear, nose and throat assessment are appropriate for new hearing loss, tinnitus or skull-base symptoms. Neurology, spine surgery or neurosurgery is needed for objective neural compression. Orthopaedics should assess fracture, progressive deformity, severe secondary osteoarthritis or a planned joint replacement. Musculoskeletal radiology or orthopaedic oncology review is urgent when there is rapid pain escalation, swelling, cortical destruction or a soft-tissue mass. Family members are not sent for indiscriminate scans; specialist counselling can consider targeted assessment in unusually early or severe familial disease.
Urgent referral is required for suspected pathological fracture, inability to bear weight, acute neurological deficit, cauda equina symptoms or malignant transformation. A stable asymptomatic radiographic lesion may not require emergency care, but it still needs diagnostic confirmation and a follow-up plan. Where nuclear medicine is unavailable in India, use specialist-directed targeted radiography and biochemistry rather than pretending the extent is known. Do not delay red-flag evaluation while obtaining a routine bone scan, and do not refer every nonspecific alkaline phosphatase rise without first checking its likely hepatic or skeletal origin.
Red Flags
New severe focal pain in a previously stable pagetic bone may represent fissure fracture, complete fracture or sarcomatous change. Swelling, a growing mass, night pain, cortical destruction, a new lytic lesion or rapid loss of function requires urgent cross-sectional imaging and orthopaedic oncology input. Paget-associated osteosarcoma is rare, so routine fear is inappropriate, but delay after a genuine change is dangerous. Biopsy planning belongs to the tumour team because an unplanned approach can compromise definitive surgery.
Spinal disease can cause stenosis, radiculopathy, myelopathy or cauda equina compression. New weakness, gait collapse, sensory level, saddle anaesthesia or bladder and bowel dysfunction requires emergency imaging and specialist assessment. Skull-base involvement can affect cranial nerves; sudden hearing change, diplopia, dysphagia or facial weakness warrants prompt evaluation. Acute inability to bear weight or deformity after minor trauma should be managed as a possible pathological fracture.
Before antiresorptive treatment, symptomatic hypocalcaemia, severe vitamin D deficiency, acute kidney injury or unsafe renal function must be corrected or reviewed. After infusion, persistent vomiting, reduced urine output, carpopedal spasm, confusion, severe ocular pain or visual loss needs urgent assessment rather than being dismissed as a flu-like reaction. Jaw pain with exposed bone and persistent thigh pain require evaluation, although their absolute risk after limited Paget treatment is low. Fever and focal warmth may indicate infection. Hypercalcaemia is not typical of uncomplicated mobile Paget disease and should trigger investigation for another condition or prolonged immobilisation.
Indian Clinical Context
Paget disease is reported far less often in India than in historically high-prevalence European populations. That lowers prior probability but does not make the condition nonexistent. A careful Indian pathway first establishes that alkaline phosphatase is bone-derived and that the radiograph is characteristic. Common alternatives include hepatobiliary disease, vitamin D-related osteomalacia, hyperparathyroidism, healing fracture and malignancy. Consultation with a musculoskeletal radiologist can prevent both missed cases and overdiagnosis from nonspecific sclerosis.
Access to radionuclide scanning, bone-turnover markers, audiology, intravenous zoledronic acid and metabolic bone specialists varies by state and sector. If a bone scan is unavailable, document that extent is incompletely assessed and prioritise symptomatic or high-consequence sites; do not claim a negative whole-skeleton evaluation. Before infusion, verify the exact Indian product, renal threshold, calcium and vitamin D plan, infusion facility and follow-up. Out-of-pocket cost and travel may favour a durable treatment but do not erase contraindications or evidence uncertainty.
The international 2019 guideline, Endocrine Society guideline and 2024 Italian position paper reflect different health systems and partially conflicting treatment philosophies. None is an Indian statutory protocol. Their transferable elements are radiographic confirmation, alkaline phosphatase assessment, extent mapping, symptom-centred outcomes and bisphosphonate safety. The NMC curriculum establishes OR7.1 as an undergraduate learning outcome. Local formulary, regulator-approved labelling and specialist judgment govern actual treatment. Registry-quality Indian data would improve prevalence and outcome estimates; until then, the guide must acknowledge uncertainty rather than manufacture a national burden or universal treatment threshold.
NMC Competency Mapping
The NMC Competency Based Medical Education curriculum includes Paget disease explicitly in Orthopaedics competency OR7.1. Learners are expected to describe and discuss the aetiopathogenesis, clinical features, investigations and principles of management of metabolic bone disorders, particularly osteoporosis, osteomalacia, rickets and Paget disease. The listed level is knowledge and know-how, with lectures, small-group discussion and case discussion; no independent procedure is certified by this competency.
A competent learner should explain coupled but disorganised high-turnover remodelling and relate it to enlarged, deformed yet mechanically weak bone. They should recognise focal bone pain, skull enlargement, bowing, hearing impairment, secondary osteoarthritis, pathological fracture and neurological compression. Investigation skills include distinguishing bone from liver alkaline phosphatase, identifying the characteristic radiographic stages, using scintigraphy to map extent after diagnosis and reserving CT, MRI or biopsy for complications and uncertain lesions.
Management knowledge includes determining whether symptoms arise from active pagetic bone or an adjacent joint, using bisphosphonates for Paget-related bone pain, preparing safely for treatment and monitoring clinical rather than purely biochemical outcomes. The learner should know that zoledronic acid has the most durable biochemical response, while evidence does not prove that treating every asymptomatic marker elevation prevents complications. Red-flag competence includes fracture, cord compression and suspected sarcoma. OR7.1 supports supervised reasoning and exam preparation; it does not authorize intravenous therapy, radionuclide interpretation, genetic counselling or oncological biopsy planning without trained specialist oversight.
Key Exam Pearls for NEET PG
Paget disease, or osteitis deformans, is focal high-turnover remodelling with excessive osteoclast activity followed by disorganised osteoblast formation. Histology shows a mosaic pattern with cement lines. Common sites are pelvis, vertebrae, skull, femur and tibia. Skull involvement can cause enlargement, hearing loss and basilar complications; long bones may bow and develop fissure fractures. Adjacent joints develop secondary osteoarthritis. Malignant transformation to osteosarcoma is rare but presents with new pain, swelling or destructive change.
Total alkaline phosphatase is the first-line biochemical marker when liver tests are normal. Calcium and phosphate are usually normal in uncomplicated ambulant disease. A normal total alkaline phosphatase does not exclude limited monostotic disease; bone-specific alkaline phosphatase or PINP may help. Plain radiographs establish the characteristic diagnosis: early osteolysis, mixed lytic-sclerotic change, cortical thickening, coarsened trabeculae and bone expansion. A radionuclide scan maps extent but is not specific enough to replace radiographs.
Treat Paget-related bone pain with a nitrogen-containing bisphosphonate; a single intravenous zoledronic acid course gives the most durable response in eligible patients. Correct hypocalcaemia and vitamin D deficiency and assess renal function first. Do not confuse biochemical relapse with clinical relapse, and do not promise prevention of hearing loss, osteoarthritis, fracture or sarcoma through marker normalisation. Exam stems often contrast Paget disease with osteomalacia, metastasis or hyperparathyroidism. The safest answer combines focal imaging, bone-derived alkaline phosphatase and complication-directed assessment rather than diagnosing from age or one laboratory value.
Frequently Asked Questions
Does every person with Paget disease and raised alkaline phosphatase need immediate treatment?
Not automatically. Strong evidence supports bisphosphonate treatment for bone pain attributable to active Paget disease. Evidence that intensive biochemical suppression prevents future complications in an asymptomatic person is insufficient, and current guidelines interpret that uncertainty differently. Site, activity, risk, comorbidity and patient preference should be reviewed with a metabolic bone specialist.
Why are both plain radiographs and a radionuclide bone scan used?
A characteristic radiograph usually establishes the diagnosis and shows structural detail. Once Paget disease is confirmed, radionuclide scanning sensitively maps other metabolically active sites, including asymptomatic lesions, but uptake is not specific and may occur in fracture, arthritis, infection or tumour. Suspicious scan sites may therefore need targeted radiographs or other imaging.
Can a normal alkaline phosphatase result exclude Paget disease of bone?
No. Total alkaline phosphatase may remain normal in limited monostotic or inactive disease. When imaging or symptoms remain persuasive, a bone-specific formation marker such as bone alkaline phosphatase or PINP and appropriate imaging may help. Liver disease can also obscure interpretation, so the result must be linked to liver tests and skeletal extent.
Which new symptoms in established Paget disease require urgent assessment?
New severe focal bone pain, inability to bear weight, deformity after minor trauma, a growing mass, rapid swelling, weakness, sensory loss, saddle anaesthesia or bladder and bowel dysfunction require urgent assessment. They may indicate fracture, spinal compression or rare malignant transformation and should not be managed simply by repeating a bisphosphonate or alkaline phosphatase test.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic